Since the beginning of the pandemic, VOXCAN and NOVOTEC have been responding to the urgent need to find solutions for SARS-CoV-2 infection. The two companies from the Rhône-Alpes-Auvergne region have joined forces to offer a preclinical service (models, tests, anatomopathological analyses, etc.) to evaluate and characterize new vaccines and therapeutic molecules before they enter clinical trials.
